Harmony Nutraceuticals LLC – Trademark Portfolio
Entity Type: 16
Harmony Nutraceuticals LLC holds 65 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 63 filings in this category. The portfolio also extends into Class 29 (Meats & Processed Foods) across 2 Nice Classification classes. Currently, 41 trademarks are registered and 4 are pending. Notable registered marks include ASHWIN, BONE'L, MILKON, ZENZONE, and CARDIONA. The owner is based in Oklahoma City, OK.
3708 NW 62nd St.
Oklahoma City, OK 73112
Showing of trademarks Trademarks
Trademark Classifications
Harmony Nutraceuticals LLC's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Meat, fish, poultry and game; meat extracts; preserved, frozen, dried and cooked fruits
Frequently Asked Questions
How many trademarks does Harmony Nutraceuticals LLC have?
Harmony Nutraceuticals LLC has 65 U.S. trademarks filed with the USPTO. Of these, 41 registered, 4 pending, 20 abandoned.
What trademark classes does Harmony Nutraceuticals LLC file in?
Harmony Nutraceuticals LLC files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 29 (Meats & Processed Foods). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Harmony Nutraceuticals LLC's most well-known trademarks?
Harmony Nutraceuticals LLC's registered trademark portfolio includes well-known marks such as ASHWIN, BONE'L, MILKON, ZENZONE, and CARDIONA. These are among 41 currently registered trademarks in the portfolio.
What is Harmony Nutraceuticals LLC's trademark registration success rate?
Harmony Nutraceuticals LLC has a 67% trademark registration rate, with 41 out of 61 resolved applications resulting in successful registration. Currently, 4 applications are pending review.